Atea Pharmaceuticals presented a hepatitis C strategy focused on short-term treatment regimens at JPM.[1][2] Their program includes two Phase III clinical trials: C-BEYOND in the US and Canada and C-FORWARD outside of North America.[1][2][5][6] Studies are evaluating the combination of bemnifosbuvir and ruzasvir compared to standard treatment with sofosbuvir and velpatasvir in adults with chronic hepatitis C.[1][2][6][8] The regimen is administered orally once daily for 8 weeks in patients without cirrhosis or 12 weeks in patients with compensated cirrhosis.[6] The primary endpoint is HCV RNA below the limit of quantification at 24 weeks post-treatment, including SVR12.[1][2][5] In a phase II study, the 8-week regimen achieved a sustained virologic response of 98% in adherent patients, with no serious drug-related adverse events.[2][3] Treatment was well tolerated, with mild to moderate adverse events occurring in 43% of patients, most commonly headache (9%) and nausea (8%).[2]